고용량 131I 치료는 분화갑상선암으로 인한 갑상선전절제술을 받은 환자에게 보편적으로 시행되어 왔다. 고용량 131I 치료를 하는 경우 환자로부터 일반인이 받게 되는 피폭선량을 선량한도 이내로 제한하기 위해 환자를 일정 기간 동안 격리하여야 한다. 유효반감기는 환자로부터 가족들이 얼마나 피폭되는지 계산하거 나 격리기간을 결정하는데 중요한 값이다. 이에 본 연구에서는 NM670 SPECT/CT를 이용해 고용량 131I 치 료환자의 유효붕괴상수, 유효반감기, 격리기간을 도출하였다. 본 연구를 통해 고용량 131I 치료환자의 유효반감기를 도출하였고, 체내에 잔류 방사능량이 퇴원기준인 1. 2 GBq 에 도달하는 시간을 확인하였다. 또한 치료선량별 유효반감기를 비교하였을 때 유의한 차이가 없 었으나, 격리기간은 치료선량이 커질수록 격리기간이 길어지는 것을 확인할 수 있었다. 전처치 유형별 유 효반감기를 비교하였을 때 rhTSH 환자군과 THW 환자군의 유효반감기가 유의한 차이를 보이지 않았으나, 격리기간은 rhTSH 환자군이 THW 환자군 보다 짧게 나타났다. 이는 치료선량의 차이로 인해 격리기간이 짧아진 것으로 판단된다. 따라서 현행 의료보험체계(rhTSH 사용 시 3.7 GBq 이하에서 보험적용)가 유지된다면, 전처치 유형별로 구분하여 현행 격리기간(2박 3일)보다 더 이른 시간에 환자를 퇴원시킬 수 있을 것이다.

High-dose 131I therapy has been generally carried out to remove remaining thyroid tissue or to cure metastasize lesion of patients who received full thyroidectomy due to differentiated thyroid cancers. In case high-dose 131I therapy is carried out for a patient, the patient should be hospitalized being isolated for a certain period in order to restrict the amount of exposure to radiation of people at large from the patient within the limit of a level of radiation. Effective half-life is an important value to calculate how family members are exposed to radiation from a patient or to decide the period of isolation of the patient from the family members. Therefore, in this study we calculated the effective decay constant, effective half-life and period of isolation of high-dose 131I therapy patient using NM670 SPECT/CT. As a result of carrying out this study, the effective half-life of high-dose 131I therapy patients was derived and the time to reach the discharge level of 1.2 GBq was confirmed. When they were compared with each other in each of curative doses, the effective half-life did not have significant difference, but the time when the level of radiation remaining in the interior of the body to reach the criteria of isolation and discharge showed significant difference and it could be confirmed that the higher the curative dose the longer the period of isolation becomes. When the effective half-lives in each type of preparation were compared with each other, they did not show significant difference. However, When the times to reach the level of radiation that is the criteria of isolation and discharge in each type of preparations, they showed significant difference. The cause of the shortening of the isolation period for rhTSH patients group is decided to be low curative dose. Accordingly, if the current national health insurance (the insurance is applied to using of rhTSH in 3.7 GBq or lower) is maintained, while discerning them in each of types of preparation, we would be able to discharge patients at the time earlier than the current period of isolation (2 nights and 3 days).

Ⅰ. INTRODUCTION
 Ⅱ. MATERIAL AND METHODS
 Ⅲ. RESULT
 Ⅳ. DISCUSSION
 Ⅴ. CONCLUSION
 Acknowledgement
 Reference

• Seongcheol Kim(Department of Radiological Science, Daegu Catholic University, Department of Nuclear Medicine, Kyungpook National University Hospital, 대구가톨릭대학교 방사선학과, 경북대학교병원 핵의학과) | 김성철
• DaYeong Gwon(Department of Radiological Science, Daegu Catholic University, 대구가톨릭대학교 방사선학과) | 권다영
• Yongmin Kim(Department of Radiological Science, Daegu Catholic University, 대구가톨릭대학교 방사선학과) | 김용민 Corresponding Author